Company profile: GeNeuro
1.1 - Company Overview
Company description
- Provider of therapeutic monoclonal antibody drugs targeting human endogenous retroviral proteins for nervous system and autoimmune diseases. Portfolio includes Temelimab for Multiple Sclerosis and long-COVID neurological/psychiatric symptoms, the GNC-501 personalized trial in post-COVID W-ENV-positive patients, and a preclinical HERV-K Env antibody for sporadic ALS.
Products and services
- GNC-501: Personalized-medicine clinical trial assessing temelimab as a Disease Modifying Therapy in post-COVID patients positive for pathogenic W-ENV protein
- HERV-K Env Antibody: Preclinical-program developing a novel antibody that targets HERV-K Env found in sporadic ALS patients, focused on Amyotrophic Lateral Sclerosis applications
- Temelimab: Clinical-stage monoclonal antibody targeting HERV-W Env, tested to stop disability progression in Multiple Sclerosis and evaluated as a Disease Modifying Therapy in long-COVID with severe neurological and psychiatric symptoms
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GeNeuro
Chestnut Medical
HQ: United States
Website
- Description: Provider of minimally invasive therapies and technologies for interventional neuroradiology, focused on improving outcomes and reducing complications in the treatment of neurovascular disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chestnut Medical company profile →
Iama Therapeutics
HQ: Italy
Website
- Description: Provider of novel neuroscience therapeutics for pediatric brain disorders, advancing drug discovery to address unmet needs; lead candidate IAMA-6 is an orally administered small molecule targeting NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for autism and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iama Therapeutics company profile →
Algynomics
HQ: United States
Website
- Description: Provider of a research-stage pain diagnostics platform leveraging patient cohorts to deliver prospective data that identifies individuals at increased risk for chronic pain, enabling targeted preventive efforts and enhancing patient stratification in clinical trials to identify treatment responders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algynomics company profile →
NICO
HQ: United States
Website
- Description: Provider of medical devices for minimally invasive neurosurgery and skull base and spinal procedures, including BrainPath for access to the subcortical space; Myriad SPECTRA for automated brain tumor removal and clot evacuation with directional light for fluorescence guidance; APS for intraoperative tissue collection and preservation; and meniGLIDE for controlled meningeal opening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NICO company profile →
Rapid Dose Therapeutics
HQ: Canada
Website
- Description: Provider of pharma-tech oral fast-dissolving drug delivery solutions, including QuickStrip for direct bloodstream delivery of pharmaceuticals and over-the-counter medicines; RDMx + QuickStrip for enabling delivery of large therapeutic molecules; Rapid Energy, Vitamin B12, and Melatonin QuickStrip products; and versions for elderly and pediatric patients needing simplified, rapid dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapid Dose Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GeNeuro
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GeNeuro
2.2 - Growth funds investing in similar companies to GeNeuro
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GeNeuro
4.2 - Public trading comparable groups for GeNeuro
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →